An equation is presented which allows infinity values for biexponential processes to be predicted in the early nonlinear phase when samples are taken at equal time intervals. This equation is independent of the value or ratio of the rate constants involved in the process. However, this method is very sensitive to noise normally associated with urine data.
INTRODUCTION
One of the methods used to assess bioavailabiIity is to determine the total amount of drug and/or metabotite(s) (infinity values) appearing in the urine. Guggenheim (1) and Amidon et al. (2) which can be used to plot the data allowing more than three observations to be used in the determination of Y~. 
which allows Y~ to be determined from the intercept of the graph and the rate constant k to be evaluated from the slope of the line, where At is the equal time interval at which samples are taken. Wagner (4) has shown that the Guggenheim equation corresponding to equation 3 may be written as
However, equation 4 will make terrible estimates of the infinity value and rate constant k from data at equal time intervals, whereas equation 3 with either ordinary or orthogonal least squares will make excellent estimates (5) .
These equations can be used in biexponential processes provided that they are applied during the terminal linear phase of the biexponential process. This could require collection of urine samples over relatively long time periods to assure being in the linear phase. The purpose of this communication is to propose an equation which will allow prediction of the infinity values for the biexponential processes during the nonlinear phase. This equation is independent of the rate constants and may be used during the early period of the study, provided that samples are taken at equal time intervals.
This technique is described in Hildebrand (6) as Prony's method of exponential approximation. It is an exact solution (non-least-squares) and can be very sensitive to noise normally associated with urine data and may produce large errors especially if there is much deviation of the data from the exact line. Included in the discussion is an example of the error which may result from rounding off the data as discussed by Hildebrand (6) .
THEORETICAL AND DISCUSSION
Juhl et al. (7) have investigated the effect of sulfasalazine on digoxin bioavailability by measuring urinary digoxin excretion. Wagner and Ayres (3) have applied various methods to these data to estimate the total amount of digoxin appearing in the urine. All of the methods used by Wagner and Ayres (3) assume that the data become linear at 3 days, and the data from this point on were fitted to various monoexponential functions. If the following equation is used (see Appendix for derivation), data points in the nonlinear phase of the process may be used, and the problem of determining when linearity begins is avoided. Also, equation 5 may be used during the early time periods, reducing the number of samples needed in the study. Table I shows the results obtained by JuhI et al. (7) , by Wagner and Ayres (3), and by using equation 5. Two sets of data are presented for equation 5 . One set uses the data points extrapolated for the first 5 days by Wagner and Ayres (3) . The other set is a combination of the 0.5, 1-, and 2-day points extrapolated by Wagner and Ayres (3) and the 1.5-and 2.5-day points extrapolated by the authors. The data points at 1.5 and 2.5 days for digoxin alone are 143 and 186 t~g, respectively, and 118 and 152.5/zg, respectively, for digoxin in the presence of sulfasalazine difference) were predicted to appear in the urine. Tables III and IV , were simulated to illustrate the sensitivity of the method as described by Hildebrand (6) . Using the solution for the one-compartment open model
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for data given to three decimal places (Table Ili) gives a result of 100.1 mg for Yoo (0.1% error). Using the data given to two decimal places gives a result of 98.49 mg for Yoo (1.51% error). Using the solution of the two-compartment model, previously shown as equation 5, for the data given to three decimal places in Table IV gives a result of 99.96 mg (0.04% error). Using the data given to two decimal places gives a result of 108.98 mg (8.98% error). 
CONCLUSIONS
An equation has 9 presented which allows prediction of infinity values for both intact drug and metabolite appearing in the urine for exponential processes, provided that samples are taken at equal time intervals. This method allows data to be used in the early nonlinear place of the biexponential process. However, this technique must be used with caution as it is very sensitive to noise which is usually associated with urine data and may result in large errors.
APPENDIX
The general equation for the biexponential process may be written as
1. Oral absorption model (single dose): Using the method of equal time intervals suggested by Guggenheim (1), such that ti = i At; i = 1, 2, 3 .... then the following equations may be written:
If equations 4a, 5a, and 6a are written as
Yoo -II2 = Ae-klat ( e -klAt ) + Be-k2a' ( e -k~a') (10a)
Y~ -Y3 = Ae-kla'(e -2kla') + Be-k2at(e -2k2a')
(1 la) then the following determinants and equalities may be written:
t) (Yoo-Y2) (e -k~a*) (e = (Y~-Y3) (e -2klan) (e -2k2at)
(e-k~A~) (e--k~A') (e--2k, A') (e-2kd") C 0 (1) (1) 0 (e -klan) (e -kla') =0 0 (e -2k~a') (e -2kzat)
Repeating this procedure for equations 5a, 6a, and 7a and again for equations 6a, 7a, and 8a allows the following determinants to be written and shows that all the resulting determinants are equal:
(1) (Yoo-Y2) (e -kIa~) (e -k2a') (Yoo-Y3) (e -2klA`) (e -2k1~') E (Yoo-Y2) (1) (1) (Y~o-I13) (e -k'~t) (e -k~a') (Y o o-Y4) (e -2klat) (e -2k2a') F (Y~-I13)
(1) (1) (Y~-Y4) (e -k'a') (e -k~' (Y o o-Y s) (e -2k~') (e -2k~')
The solution for determinant D can be obtained by letting x = e -klAt, X 2 = e -2klAt, y = e -k2a~, and y2 = -2k2at. Thus 
(Yoo-Y1)(xy2-yx2)-(Y~o -Y2)(ya-x2)+(Y~ -
Y3
